Envista Holdings Corp

Envista Holdings Corporation raised its full-year 2026 guidance after reporting second-quarter sales of US$730.5 million and net income of US$53.7 million, with earnings per share from continuing operations reaching US$0.33. The company also completed share repurchases totaling 12,458,894 shares for US$250 million, retiring about 7.4% of shares outstanding. The upgraded outlook comes despite expected pricing pressure in China related to Volume Based Procurement policies. The raised guidance and first-half earnings momentum support the near-term earnings story, though the China policy risk remains a significant concern.

Envista Holdings Corporation reported second-quarter 2026 sales of $731 million, up just over 7% year over year with 5% core growth, and raised its full-year guidance. Adjusted EBITDA rose 28% to a 14.7% margin, adjusted earnings per share increased 58% to $0.41, and free cash flow reached $105 million. The Equipment and Consumables segment posted 8.5% core growth, while Specialty Products & Technologies grew 3.1%, supported by double-digit Spark clear-aligner growth. Management now expects 2026 core sales growth of 3.5% to 4.5%, adjusted EBITDA growth of 11% to 14%, and adjusted earnings per share of $1.50 to $1.55, while cautioning that China's expected orthodontic and implant procurement programs could create pricing pressure in the second half.

Envista Holdings is well-positioned for growth driven by its three strategic priorities and targeted acquisitions, though macroeconomic uncertainty and currency fluctuations pose challenges. In the first quarter of 2026, the Specialty Products & Technologies segment posted 8.4% core growth and the Equipment and Consumables segment grew 11.5%, while the Envista Business System helped expand gross margin by 100 basis points and adjusted EBITDA margin by 120 basis points. The company acquired Versah for about $54.7 million, adding the Densah Burs system for osseodensification, and management expects the deal to be accretive to growth, margins, and earnings per share. Developed markets led growth with double-digit gains in North America and Europe, and the Spark clear aligner launch in Japan opens a new growth vector in a sizable market. However, tariff costs increased $11 million year-over-year in the first quarter, and China remains a source of uncertainty as channel partners adjust inventory ahead of the anticipated volume-based procurement process expected between the second and third quarters.

Envista Holdings Corporation reiterated its full-year guidance following a strong first quarter, with sales expected to grow between 2% and 4% and adjusted EBITDA between 7% and 13%. The company reported 9.5% core revenue growth in the quarter, which translated into 25% adjusted EBITDA growth and 50% earnings-per-share growth. Barclays reiterated an Overweight rating on the stock on June 11 but lowered the price target to $32 from $34, noting that Envista's end markets continue to stabilize. Envista Holdings is a global medical technology company that develops, manufactures, and markets dental products and equipment under more than 30 brands including Nobel Biocare, Ormco, DEXIS, and Kerr.

The global dental consumables market is projected to grow from USD 37.0 billion in 2026 to USD 54.0 billion by 2031, registering a CAGR of 7.9%. The increasing incidence of dental caries, periodontal diseases, and tooth loss is creating sustained demand for preventive, restorative, and therapeutic consumables. Dental restoration materials accounted for the largest product segment in 2025, driven by high volumes of restorative procedures such as fillings, crowns, and bridges. Dental hospitals and clinics represented the largest end-user segment due to their role as primary providers of dental care services. Asia Pacific is expected to register the highest growth rate, supported by rising healthcare expenditure, growing middle-class populations, and expanding dental tourism in countries like India, Thailand, and South Korea. Major companies include Institut Straumann AG, Envista, Dentsply Sirona, ZimVie Inc., and Solventum.

Envista Holdings shares have surged 37.1% over the past 12 months, far outpacing the dental products industry's 30.3% decline and the S&P 500's 28.2% gain. The company's first-quarter 2026 results showed 8.4% core growth in Specialty Products & Technologies and 11.5% in Equipment and Consumables, driven by new product launches including the Nobel S Series implants, Spark clear aligners in Japan, and AI-enhanced DEXIS software. Gross margin expanded 100 basis points and adjusted EBITDA margin rose 120 basis points, even as the company offset an $11 million increase in tariff costs. Envista also acquired Versah for about $54.7 million, adding the Densah Burs osseodensification system to its implant portfolio. The Zacks Consensus Estimate projects 2026 earnings per share of $1.42, up 19.3% year over year, on revenue of $2.86 billion.